You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: February 29, 2024

GEODON Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Geodon patents expire, and when can generic versions of Geodon launch?

Geodon is a drug marketed by Viatris and Pfizer Inc and is included in three NDAs.

The generic ingredient in GEODON is ziprasidone mesylate. There are twenty-three drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the ziprasidone mesylate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Geodon

A generic version of GEODON was approved as ziprasidone mesylate by GLAND PHARMA LTD on December 26th, 2019.

  Try a Trial

Drug patent expirations by year for GEODON
Drug Prices for GEODON

See drug prices for GEODON

Drug Sales Revenue Trends for GEODON

See drug sales revenues for GEODON

Recent Clinical Trials for GEODON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Astellas Pharma Global Development, Inc.Phase 2
Duke UniversityPhase 1
National Heart, Lung, and Blood Institute (NHLBI)Phase 1

See all GEODON clinical trials

Pharmacology for GEODON
Anatomical Therapeutic Chemical (ATC) Classes for GEODON
Paragraph IV (Patent) Challenges for GEODON
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
GEODON Capsules ziprasidone hydrochloride 20 mg, 40 mg, 60 mg and 80 mg 020825 5 2005-02-07

US Patents and Regulatory Information for GEODON

GEODON is protected by zero US patents and one FDA Regulatory Exclusivity.

FDA Regulatory Exclusivity protecting GEODON

INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viatris GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-001 Feb 5, 2001 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Viatris GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-004 Feb 5, 2001 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Viatris GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-002 Feb 5, 2001 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Viatris GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-003 Feb 5, 2001 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for GEODON

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Inc GEODON ziprasidone hydrochloride SUSPENSION;ORAL 021483-001 Mar 29, 2006 ⤷  Try a Trial ⤷  Try a Trial
Viatris GEODON ziprasidone mesylate POWDER;INTRAMUSCULAR 020919-001 Jun 21, 2002 ⤷  Try a Trial ⤷  Try a Trial
Viatris GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-004 Feb 5, 2001 ⤷  Try a Trial ⤷  Try a Trial
Viatris GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-002 Feb 5, 2001 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for GEODON

See the table below for patents covering GEODON around the world.

Country Patent Number Title Estimated Expiration
Japan 3102896 ⤷  Try a Trial
Brazil 0010990 ⤷  Try a Trial
Czech Republic 297954 Farmaceutická kompozice na bázi ziprasidonu a zpusob výroby velkých krystalu monohydrátu hydrochloridu ziprasidonu (Ziprasidone-based pharmaceutical composition and process for preparing large crystals of ziprasidone hydrochloride monohydrate) ⤷  Try a Trial
Czech Republic 9300877 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for GEODON

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0904273 PA2003004,C0904273 Lithuania ⤷  Try a Trial PRODUCT NAME: ZIPRASIDONUM (5-(2-(4-(1,2-BENZIZOTIAZOL-3-IL)-1-PIPERAZINIL)ETIL)-6-CHLOR-1,3-DIHIDRO-2H-INDOL-2-ONAS); REGISTRATION NO/DATE: 02/7887/8 20021002
0904273 PA2003004 Lithuania ⤷  Try a Trial PRODUCT NAME: ZIPRASIDONUM (5-(2-(4-(1,2-BENZIZOTIAZOL-3-IL)-1-PIPERAZINIL)ETIL)-6-CHLOR-1,3-DIHIDRO-2H-INDOL-2-ONAS); REGISTRATION NO/DATE: 02/7887/8 20021002
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.